Selective renal arterial infusion of fenoldopam for the prevention of contrast-induced nephropathy

Journal of Interventional Cardiology

Volumn 19, Issue 1, 2006, Pages 75-79

  Ng, Martin K C ^a,b   Tremmel, Jennifer ^a   Fitzgerald, Peter J ^a   Fearon, William F ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; EPTIFIBATIDE; FENOLDOPAM; HEPARIN; IODIXANOL; PACLITAXEL;

ADULT; ANGIOGRAPHY; ARTICLE; CASE REPORT; DIABETES MELLITUS; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; HYPOTENSION; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY FAILURE; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; STENT; VASODILATATION;

CATHETERIZATION; CONTRAST MEDIA; FENOLDOPAM; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL ARTERY; STENTS; VASODILATOR AGENTS;

EID: 33645297666     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2006.00108.x     Document Type: Article

References (15)

1. Rihal C Textor S Grill D et al.. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002 105 2259 2264.
2. Cox C Tsikouris J. Preventing contrast nephropathy: What is the best strategy? A review of the literature. J Clin Pharmacol 2004 44 327 337.
3. Stone G McCullough P Tumlin J et al.. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA 2003 290 2284 2291.
4. Madyoon H Teirstein P Baim D et al.. Differential effects between intravenous and local renal delivery of fenoldopam on renal function and blood pressure: A randomized, controlled trial. Am J Cardiol 2004 94 22E 23E.
5. Grube E Teirstein P Baim D et al.. Intrarenal fenoldopam increases renal artery velocity and causes fewer effects on blood pressure lowering than intravenous fenoldopam. Am J Cardiol 2004 94 176E.
6. McCullough P Sandberg K. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003 4 S3 S9.
7. Deray G Baumelou B Martinez F et al.. Renal vasoconstriction after low and high osmolar contrast agents in ischemic and non ischemic canine kidney. Clin Nephrol 1991 36 93 96.
8. Russo D Minutolo R Cianciaruso B et al.. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995 6 1451 1458.
9. Liss P Nygren A Olsson U et al.. Effects of contrast media and mannitol on renal medullary blood flow and red cell aggregation in the rat kidney. Kidney Int 1996 49 1268 1275.
10. Idee J Lancelot E Pines E et al.. Prophylaxis of iodinated contrast media-induced nephropathy: A pharmacological point of view. Invest Radiol 2004 39 155 170.
11. Tumlin J Wang A Murray P et al.. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy. Am Heart J 2002 143 894 903.
12. Singer I Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis 1998 31 743 755.
13. Madyoon H Croushore L Weaver D et al.. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interven 2001 53 341 345.
14. Kini AS Mitre CA Kim M et al.. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: Effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interven 2002 55 169 173.
15. Allaqaband S Tumuluri R Malik A et al.. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interven 2002 57 279 283.